背景:MicroRNA-146b(miR-146b)是几种血液系统恶性肿瘤的关键调节因子和预后生物标志物,而其在多发性骨髓瘤(MM)中的作用尚不清楚。因此,本研究旨在探讨miR-146b在MM患者中的意义。
方法:从180例有症状的MM患者(治疗前)和50例健康对照(HC)的骨髓样本中分离浆细胞,随后通过逆转录-定量聚合酶链反应检测miR-146b的表达。
结果:与HCs相比,MM患者的MiR-146b升高(P<.001),并预测MM风险增加(曲线下面积(AUC):0.879,95%置信区间(CI):0.822-0.936)。对于临床参数,miR-146b与血清肌酐呈正相关(P=0.047)。β-2-微球蛋白(P<.001),乳酸脱氢酶(P<.001),骨损伤(P=.027),国际分期系统(ISS)阶段(P<.001),和t(4;14;P=.006),MM患者与白蛋白呈负相关(P=.004)。为了预后,与非CR患者相比,完全反应(CR)患者的miR-146b降低(P=0.025),以及总反应率(ORR)患者与非ORR患者相比(P=0.036),在MM患者中,将CR患者与非CR患者区分开(AUC:0.610,95%CI:0.523-0.698),将ORR患者与非ORR患者区分开(AUC:0.602,95%CI:0.501-0.703)。此外,miR-146b与MM患者无进展生存期(P=.007)和总生存期(P=.014)相关。
结论:MiR-146b在MM患者中过度表达,预测MM风险增加;它与恶化的临床特性有关,增加国际空间站的舞台,cacethic染色体异常,MM患者预后较差。
BACKGROUND: MicroRNA-146b (miR-146b) is a critical regulator and prognosis biomarker in several hematological malignancies, whereas its role in multiple myeloma (MM) was unclear. Therefore, this study aimed to investigate the significance of miR-146b in MM patients.
METHODS: The plasma cells were separated from bone marrow samples of 180 symptomatic MM patients (before treatment) and 50 healthy controls (HCs), and subsequently detected by reverse transcription-quantitative polymerase chain reaction for miR-146b expression.
RESULTS: MiR-146b was increased in MM patients compared with HCs (P < .001), and it predicted increased MM risk (area under curve (AUC): 0.879, 95% confidence interval (CI): 0.822-0.936). For clinical parameters, miR-146b was positively correlated with serum creatinine (P = .047), beta-2-microglobulin (P < .001), lactate dehydrogenase (P < .001), bone lesion (P = .027), International Staging System (ISS) stage (P < .001), and t (4; 14; P = .006), while negatively correlated with albumin (P = .004) in MM patients. For prognosis, miR-146b was decreased in complete response (CR) patients compared with non-CR patients (P = .025), as well as in overall response rate (ORR) patients compared with non-ORR patients (P = .036), and it discriminated CR patients from non-CR patients (AUC: 0.610, 95% CI: 0.523-0.698) and distinguished ORR patients from non-ORR patients (AUC: 0.602, 95% CI: 0.501-0.703) in MM patients. Moreover, miR-146b was correlated with worse progression-free survival (P = .007) and overall survival (P = .014) in MM patients.
CONCLUSIONS: MiR-146b was overexpressed in MM patients and predicted increased MM risk; meanwhile, it correlated with deteriorated clinical properties, increased ISS stage, cacoethic chromosome abnormality, and worse prognosis in MM patients.